CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) will release its first-quarter 2026 financial results on Wednesday, May 6, 2026, before U.S. markets open and will host a webcast at 8 a.m. Eastern Time.
The webcast will be available through the company’s investor relations website at https://ir.madrigalpharma.com/events-and-presentations.
The company said a replay will be available approximately two hours after the live event.
Madrigal Pharmaceuticals develops treatments for metabolic dysfunction-associated steatohepatitis, a liver disease.
Its drug Rezdiffra (resmetirom) is approved by the U.S. Food and Drug Administration and the European Commission for patients with MASH and moderate to advanced fibrosis.
A Phase 3 trial is underway to evaluate the drug for patients with compensated MASH cirrhosis.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.